| Members |
targetComponentId |
| medicinskt jod |
Iodine |
| läkemedel med behandlingsfunktion mot gikt |
Uricosuric agent |
| läkemedel med behandlingsfunktion som motgift |
Product containing antivenom (product) |
| Medicinal product containing mercury and/or mercury compound and acting as diuretic agent (product) |
Mercurial diuretic agent |
| läkemedel som innehåller triazolantimykotika |
Triazole antifungal agent |
| Medroxyprogesterone 5mg / Conjugated Estrogens 625microgram tablet |
Product containing precisely conjugated estrogen 625 microgram and medroxyprogesterone acetate 5 milligram/1 each conventional release oral tablet (clinical drug) |
| medroxiprogesteronacetat 104 mg, injektionsvätska, suspension, förfylld spruta 0,65 ml |
Medroxyprogesterone acetate 160 mg/mL suspension for injection |
| Medullary carcinoma with amyloid stroma |
Medullary carcinoma with amyloid stroma |
| medulloblastom |
Medulloblastoma |
| Mefloquine hydrochloride 250mg tablet |
Product containing precisely mefloquine (as mefloquine hydrochloride) 250 milligram/1 each conventional release oral tablet (clinical drug) |
| megaconial myopati |
Megaconial congenital muscular dystrophy |
| Megakaryoblast |
Megakaryoblast |
| Megakaryocyte |
Megakaryocyte |
| Megarectum |
Acquired megacolon |
| Meglumin iotroxinate |
Product containing iotroxic acid (medicinal product) |
| megluminjotalamat 60 %, infusionsvätska, lösning, flaska |
Iothalamate only product |
| melanocytnevus, kategori |
Pigmented nevus |
| melanoma in situ, indelning efter lokalisation |
Melanoma in situ |
| vaccin mot melanom |
Vaccine product |
| melanomvaccin |
Vaccine product |
| Melanoma: [skin] or [malignant] |
Malignant melanoma |
| Melanoma: [skin] or [malignant] |
Malignant melanoma |
| melanotisk neuroektodermal tumör hos barn |
Melanotic neuroectodermal tumor of infancy |
| Melasian type |
Melasian type |
| memantin 2 mg/ml, oral lösning |
Memantine hydrochloride 2 mg/mL oral solution |
| Membrane metallo-endopeptidase |
Lymphocyte antigen CD10 |
| Memory disturbance (& amnesia (& symptom)) |
Memory impairment (finding) |
| Memory impairment |
Memory impairment (finding) |
| meningeal tumör, oklart om benign eller malign |
Meningioma of uncertain behavior (morphologic abnormality) |
| meningiom |
Benign meningioma |
| biverkning av vaccin med meningokockpolysackarid |
Adverse reaction to meningococcal vaccine |
| Menopausal &/or postmenopausal disorders |
Disorder associated with menstruation AND/OR menopause |
| menopausala och postmenopausala sjukdomstillstånd |
Disorder associated with menstruation AND/OR menopause |
| Menopausal and postmenopausal disorders |
Disorder associated with menstruation AND/OR menopause |
| Menstrual molimen |
Premenstrual tension syndrome |
| Mental &/or developmental handicap screen |
Screening for developmental disorder (procedure) |
| Mental &/or developmental handicap screen |
Screening for developmental disorder (procedure) |
| Mental disorder - unspecified whether during pregnancy or the puerperium |
Mental disorders during pregnancy, childbirth and the puerperium |
| Mental disorder during pregnancy, childbirth or the puerperium NOS |
Mental disorders during pregnancy, childbirth and the puerperium |
| psykisk funktionsnedsättning |
Intellectual disability |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap (specialty) |
Intellectual disability specialty |
| psykisk funktionsnedsättning |
Intellectual disability specialty |
| avdelning för personer med psykisk funktionsnedsättning |
Intellectual disability psychiatry department (environment) |
| psykiatrisk vård för personer med psykisk funktionsnedsättning |
Intellectual disability psychiatry service |
| årlig fysisk undersökning av psykisk hälsa utförd |
Annual physical examination for people with mental illness completed |
| vårdplan för krisreaktion |
Mental health crisis plan |
| personlig hälsoplan för psykisk hälsa |
Mental health personal health plan |
| mental retardation |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| screening för mental retardation |
Intellectual disability screening |
| screening för psykisk funktionsnedsättning/utvecklingsstörning |
Screening for developmental disorder (procedure) |
| Mental/developmental handicap screening NOS |
Screening for developmental disorder (procedure) |
| Mental/developmental handicap screening NOS |
Screening for developmental disorder (procedure) |
| mentol 35,55 mg, inhalationskapsel |
Product containing only menthol in pulmonary dose form (medicinal product form) |
| Mepacrine hydrochloride 100mg tablet |
Mepacrine hydrochloride 100 mg oral tablet |
| petidinhydroklorid 100 mg/ml, injektionsvätska, lösning, ampull |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| petidinhydroklorid 50 mg/5 ml, sirap |
Pethidine hydrochloride 10 mg/mL oral solution |
| petidinhydroklorid 50 mg/ml, injektionsvätska, lösning, ampull |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| petidinhydroklorid 50 mg + prometazinhydroklorid 50 mg, injektionsvätska, lösning, flaska |
Product containing only pethidine and promethazine (medicinal product) |
| mepivakainhydroklorid 3 % + levonordefrin 1:20 000, injektionsvätska, lösning, flaska |
Corbadrine 50 microgram/mL and mepivacaine hydrochloride 30 mg/mL solution for injection |
| mepivakainhydroklorid 30 mg + natriumklorid 3 mg, injektionsvätska, lösning, flaska |
Mepivacaine only product |
| Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
| mepivakainhydroklorid 2 % + adrenalin 1:100 000, cylinderampull |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
| Meptazinol 100mg/1mL injection |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| meptazinol 100 mg/ml, injektionsvätska, lösning, ampull 1 ml |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 200mg tablet |
Meptazinol (as meptazinol hydrochloride) 200 mg oral tablet |
| merkurofyllininjektion |
Mercurophylline |
| mersilenpatch |
Polyester mesh (physical object) |
| Mesalamine 250mg capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| mesalazin250 mg, kapsel med modifierad frisättning |
Product containing only mesalazine in oral dose form (medicinal product form) |
| mesalazin 250 mg, depåkapsel |
Product containing only mesalazine in oral dose form (medicinal product form) |
| mesalazin 375 mg, kapsel med modifierad frisättning |
Product containing only mesalazine in oral dose form (medicinal product form) |
| mesalazin 375 mg, depåkapsel |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine 1g/100mL retention enema |
Mesalazine only product in rectal dose form |
| mesalazin 1 g/100 ml, retentionslavemang |
Mesalazine only product in rectal dose form |
| mesalazin 2 g/ 59 ml, rektalvätska |
Mesalazine only product in rectal dose form |
| mesalazin 500 mg/dospåse, entero- och depågranulat |
Product containing only mesalazine in oral dose form (medicinal product form) |
| mesalazin 500 mg, dospåse med granulat med modifierad frisättning |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine duplicate deleted |
Product containing mesalazine (medicinal product) |
| Mesenteric venous thrombosis |
Thrombosis of mesenteric vein |
| Mesio-occlusion |
Mesio-occlusion of teeth |
| mesonefrisk tumör |
Wolffian tumor of uncertain behavior (morphologic abnormality) |
| mesoridazinbesylat 10 mg/ml, injektionsvätska, lösning, ampull |
Product containing precisely mesoridazine 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| mesoridazinbesylat 25 mg/ml, injektionsvätska, lösning, ampull |
Product containing precisely mesoridazine 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mesothelioma, biphasic, benign |
Mesothelioma, benign |
| metabol acidos orsakad av intag av läkemedel och/eller kemikalier |
Metabolic acidosis |
| Metabolic disease, NEC |
Metabolic disease |
| metabol markör |
Inborn errors of metabolism marker |
| Metaiodobenzylguanidine[123I] 74MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| metajodbensylguanidin (^123^) 74 MBq/ml pulver till injektionsvätska, flaska |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I] 37MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| metajodbensylguanidin (^131^I) 35 MBq/ml, pulver till injektionsvätska, flaska |
Iobenguane (131-I)-containing product in parenteral dose form |
| metajodbensylguanidin (^131^I) 370 MBq/ml, injektionsvätska |
Iobenguane (131-I)-containing product in parenteral dose form |
| metajodbensylguanidin (^131^I) 37 MBq/ml, diagnostisk injektionsvätska |
Iobenguane (131-I)-containing product in parenteral dose form |
| metajodbensylguanidin (131I) 9,25 MBq/ml, diagnostisk injektionsvätska |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metallocarboxypeptidase |
Metallocarboxypeptidase |
| Metalloproteinase |
Metalloproteinase (substance) |
| Metaproterenol 20mg tablet |
Orciprenaline sulfate 20 mg oral tablet |
FHIR